Messenger RNA (mRNA) has gained significant attention since being used in the Pfizer-BioNTech and Moderna COVID-19 vaccines. mRNA holds potential for preventing and treating many difficult-to-treat or genetic diseases, including cancers. However, its production is complex and raises challenges for researchers developing new therapies: Discover Tebubio.
Kurma closes new fund at €250m
Latest NewsKurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies.
Well Prepared to Tackle New Pandemics
Sponsored PublicationsIf you want to successfully guard against future pandemics, you’re going to need a good plan – and the right kind of vaccine producers. WACKER and CordenPharma have been commissioned by the German government to prepare their mRNA vaccine production lines for a new pandemic.
Your mRNA Partner in Europe
BackgroundMessenger RNA (mRNA) has gained significant attention since being used in the Pfizer-BioNTech and Moderna COVID-19 vaccines. mRNA holds potential for preventing and treating many difficult-to-treat or genetic diseases, including cancers. However, its production is complex and raises challenges for researchers developing new therapies: Discover Tebubio.
Genentech takes over Regor’s RGT-419B for US$850m upfront
Latest NewsGenentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company’s breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics’ RGT-419B for US$850m.
Spima Therapeutics starts with global licence agreement
Latest NewsSPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001
EFSA updates guidelines on cultured proteins and Novel Food
Latest NewsThe EU’s food watchdog EFSA has updated its guidelines for novel food applications including cell-based and fermented foods to streamline approval times and clarify that food safety is its highest priority when recommending novel food products for market authorisation.
Patient-Centric CDMO Services – Expertise in Bioprocess Tech Transfers
Sponsored PublicationsAs a Contract Development and Manufacturing Organization (CDMO), mAbxience is committed to advancing biologics production and to ensuring that patients receive life-saving treatments faster and with uncompromising quality.
Lab Reagents made with ARTES – recombinant Proteins for lab research
ProductsARTES offers a brand-new business area making the hearts of all R&D staff beat faster. We have a whole range of first-class antigens, enzymes and functional proteins just waiting to be used in new, exciting projects.
Long version of The BIOSECURE Act: The West’s Wake-Up Call to China’s Biotech Dominance
Latest NewsBy Jeremy Levin, D.Phil, MB BChir
The importance of disaccharide excipients in biologics
Sponsored PublicationsDFE Pharma, a world leader in excipients, has expanded into the biopharmaceutical market with its BioHale® portfolio, specifically designed for biologics.